• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study

by MM360 Staff | Sep 13, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma

by MM360 Staff | Sep 11, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma

by MM360 Staff | Sep 7, 2025 | Uncategorized

Source: CureToday articles Data from the AQUILA study support the use of fixed-duration subcutaneous Darzalex Faspro as an early treatment option in high-risk smoldering myeloma. Read More

A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients

by MM360 Staff | Sep 3, 2025 | Publications

ESMO Open. 2025 Aug;10(8):105514. doi: 10.1016/j.esmoop.2025.105514. Epub 2025 Jul 15. ABSTRACT BACKGROUND: The treatment landscape for relapsed/refractory multiple myeloma (RRMM) is rapidly evolving, particularly for patients exposed or refractory to lenalidomide....

Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma

by MM360 Staff | Sep 3, 2025 | Myeloma News

Source: Pharmacy Times articles Subcutaneous bortezomib shows fewer adverse effects in multiple myeloma treatment compared to intravenous administration, enhancing patient outcomes. Read More
« Older Entries
Next Entries »

Recent Content

  • Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression
  • (no title)
  • (no title)
  • Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes
  • 35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
  • Hypoalbuminemia: a new risk factor for progression in patients with monoclonal gammopathy of uncertain significance
  • Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies
  • (no title)
  • FDA OK’s belantamab mafodotin-blmf for multiple myeloma
  • Using RNA-seq for detecting MRD in multiple myeloma: high sensitivity and prognostic value
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT